Treatment of newly diagnosed myeloma: Bortezomib-based triplet

Archana M. Rajan, S Vincent Rajkumar

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens. Carfilzomib-lenalidomide-dexamethasone (KRD) is an alternative promising regimen but has only been evaluated in small phase II studies in the frontline setting. More data are needed before this regimen can be recommended to standard risk patients with newly diagnosed myeloma. A phase III trial comparing VRD and KRD is ongoing.

Original languageEnglish (US)
Pages (from-to)700-702
Number of pages3
JournalSeminars in Oncology
Volume43
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Dexamethasone
Survival
Stem Cell Transplantation
Therapeutics
Bortezomib
lenalidomide
carfilzomib

Keywords

  • Chemotherapy
  • Myeloma
  • Prognosis
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Treatment of newly diagnosed myeloma : Bortezomib-based triplet. / Rajan, Archana M.; Rajkumar, S Vincent.

In: Seminars in Oncology, Vol. 43, No. 6, 01.12.2016, p. 700-702.

Research output: Contribution to journalReview article

@article{36b67dc7fb384c4492228ad2abfcb2e7,
title = "Treatment of newly diagnosed myeloma: Bortezomib-based triplet",
abstract = "We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens. Carfilzomib-lenalidomide-dexamethasone (KRD) is an alternative promising regimen but has only been evaluated in small phase II studies in the frontline setting. More data are needed before this regimen can be recommended to standard risk patients with newly diagnosed myeloma. A phase III trial comparing VRD and KRD is ongoing.",
keywords = "Chemotherapy, Myeloma, Prognosis, Treatment",
author = "Rajan, {Archana M.} and Rajkumar, {S Vincent}",
year = "2016",
month = "12",
day = "1",
doi = "10.1053/j.seminoncol.2016.11.003",
language = "English (US)",
volume = "43",
pages = "700--702",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Treatment of newly diagnosed myeloma

T2 - Bortezomib-based triplet

AU - Rajan, Archana M.

AU - Rajkumar, S Vincent

PY - 2016/12/1

Y1 - 2016/12/1

N2 - We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens. Carfilzomib-lenalidomide-dexamethasone (KRD) is an alternative promising regimen but has only been evaluated in small phase II studies in the frontline setting. More data are needed before this regimen can be recommended to standard risk patients with newly diagnosed myeloma. A phase III trial comparing VRD and KRD is ongoing.

AB - We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens. Carfilzomib-lenalidomide-dexamethasone (KRD) is an alternative promising regimen but has only been evaluated in small phase II studies in the frontline setting. More data are needed before this regimen can be recommended to standard risk patients with newly diagnosed myeloma. A phase III trial comparing VRD and KRD is ongoing.

KW - Chemotherapy

KW - Myeloma

KW - Prognosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85009143773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009143773&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2016.11.003

DO - 10.1053/j.seminoncol.2016.11.003

M3 - Review article

C2 - 28061990

AN - SCOPUS:85009143773

VL - 43

SP - 700

EP - 702

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -